SCHEMBL20135557

SCHEMBL20135557

Cc1ccc(-c2cc(C3CCN(C(=O)OCc4ccccc4)CC3)n[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPC3 Q13507 2/20 0.53
TRPC7 Q9HCX4 2/20 0.53
KDM4E B2RXH2 1/20 0.52
ALDH1A1 P00352 1/20 0.52
HPGD P15428 1/20 0.52
HSD17B10 Q99714 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
GRIN2B Q13224 7/20 0.49
PRMT5 O14744 1/20 0.49
USP30 Q70CQ3 1/20 0.49
CYP2C19 P33261 1/20 0.48
HTT P42858 1/20 0.45
JAK2 O60674 3/20 0.44
JAK1 P23458 3/20 0.44
TYK2 P29597 3/20 0.44
JAK3 P52333 2/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16648631 0.81 SMN1; SMN2 (0.57) TRPC3TRPC7KDM4EALDH1A1HPGD
SCHEMBL171472 0.79 SMN1; SMN2 (0.58) TRPC3TRPC7SMN1; SMN2NPC1RAB9A
SCHEMBL3100698 0.79 MGLL (0.55) TRPC3TRPC7KDM4EALDH1A1HPGD
SCHEMBL2527780 0.79 SMN1; SMN2 (0.53) TRPC3TRPC7KDM4EALDH1A1HPGD
SCHEMBL2523964 0.77 SMN1; SMN2 (0.53) TRPC3TRPC7ALDH1A1SMN1; SMN2NPC1
SCHEMBL19385266 0.76 USP30 (0.59) TRPC3TRPC7SMN1; SMN2NPC1RAB9A
SCHEMBL16648425 0.76 USP30 (0.50) TRPC3TRPC7SMN1; SMN2NPC1RAB9A
SCHEMBL3093698 0.75 MGLL (0.55) TRPC3TRPC7SMN1; SMN2NPC1RAB9A
SCHEMBL19405175 0.74 PDE4B (0.63) ALDH1A1SMN1; SMN2NPC1RAB9AGRIN2B
SCHEMBL2524272 0.74 SMN1; SMN2 (0.52) TRPC3TRPC7KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 TRPC3 2310/4885TRPC7 2501/4885KDM4E 725/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 TRPC3 2490/4885TRPC7 2710/4885KDM4E 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.